Tags

Type your tag names separated by a space and hit enter

Increased immunoreactivity against human cytomegalovirus UL83 in systemic sclerosis.
Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 106(4):31-34.CE

Abstract

OBJECTIVES

To study immunoreactivity against human cytomegalovirus (HCMV) in systemic sclerosis (SSc), since HCMV has been put forward as a candidate infectious cause.

METHODS

Eighty four patients with SSc (67 females; median age 60 years, range 25-81), 30 patients with multiple sclerosis (MS) (23 females; median age 44, range 20-69 years) and 28 healthy controls (NCs), all pre-tested positive for IgG anti-HCMV antibodies, were studied. IgG anti-UL83 HCMV antibodies were tested by western immunoblotting and expressed in arbitrary units (AUs). Reactivity to UL83 HCMV was assessed in relation to clinical manifestations and SSc-related autoantibodies (autoAbs), tested by an IgG SSc autoantibody profile line immunoassay (Euroimmun) that detects autoAbs against Scl-70, CENPA, CENPB, RNA polymerase III subunit 11 (RP11), RP155, fibrillarin, NOR90, Th/To, PM-Scl100, PM-Scl75, Ku, PDGFR and Ro-52.

RESULTS

Fifty patients (59.5%) were anti-UL83 clear positive (UL83+), including 21/40 (52.5%) lcSSc and 29/44 (65.6%) dcSSc, compared to 15/30 (50%) patients with MS (SSc vs MS, p=ns and 11/28 (39.29%) of NCs (SSc vs NC, p=ns MS vs NC, p=ns). Anti-UL83 antibody AU levels (mean±SD) were higher in SSc (64.3 ± 26) compared to MS (49.1±21.6, p=0.05) or NCs (40.4±13.7, p<0.001; MS vs NCs, p=ns) and were associated with pulmonary fibrosis.

CONCLUSIONS

Immunoreactivity to UL83 HCMV is frequent and strong in patients with SSc, implying a possible pathogenic role for this disease.

Authors+Show Affiliations

Dept. Rheumatology & Clin. Immunol., School Health Sciences, Univ.of Thessaly, Larissa; and Cellular Immunotherapy & Molecular Immunodiagnostics, Biomedical Section, Ctre for Res. & Technology-Hellas (CERTH)- Inst. Research & Technology-Thessaly, Greece.Dept. Rheumatology & Clin. Immunol., School Health Sciences, Univ.of Thessaly, Larissa; and Cellular Immunotherapy & Molecular Immunodiagnostics, Biomedical Section, Ctre for Res. & Technology-Hellas (CERTH)- Inst. Research & Technology-Thessaly, Greece.Dept. Rheumatology & Clin. Immunol., School Health Sciences, Univ.of Thessaly, Larissa; and Cellular Immunotherapy & Molecular Immunodiagnostics, Biomedical Section, Ctre for Res. & Technology-Hellas (CERTH)- Inst. Research & Technology-Thessaly, Greece.Department of Neurology, University General Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.Department of Gynaecology and Obstetrics, University General Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.Institute of Immunology, Euroimmun, Lübeck, Germany.Institute of Immunology, Euroimmun, Lübeck, Germany.Department of Neurology, University General Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.Dept. Rheumatology & Clin. Immunol., School Health Sciences, Univ.of Thessaly, Larissa; and Cellular Immunotherapy & Molecular Immunodiagnostics, Biomedical Section, Ctre for Res. & Technology-Hellas (CERTH)- Inst. Research & Technology-Thessaly, Greece.Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece. lsakkas@med.uth.gr.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28240591

Citation

Marou, Emmanouela, et al. "Increased Immunoreactivity Against Human Cytomegalovirus UL83 in Systemic Sclerosis." Clinical and Experimental Rheumatology, vol. 35 Suppl 106, no. 4, 2017, pp. 31-34.
Marou E, Liaskos C, Efthymiou G, et al. Increased immunoreactivity against human cytomegalovirus UL83 in systemic sclerosis. Clin Exp Rheumatol. 2017;35 Suppl 106(4):31-34.
Marou, E., Liaskos, C., Efthymiou, G., Dardiotis, E., Daponte, A., Scheper, T., Meyer, W., Hadjigeorgiou, G., Bogdanos, D. P., & Sakkas, L. I. (2017). Increased immunoreactivity against human cytomegalovirus UL83 in systemic sclerosis. Clinical and Experimental Rheumatology, 35 Suppl 106(4), 31-34.
Marou E, et al. Increased Immunoreactivity Against Human Cytomegalovirus UL83 in Systemic Sclerosis. Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):31-34. PubMed PMID: 28240591.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Increased immunoreactivity against human cytomegalovirus UL83 in systemic sclerosis. AU - Marou,Emmanouela, AU - Liaskos,Christos, AU - Efthymiou,Georgios, AU - Dardiotis,Efthymios, AU - Daponte,Alexandros, AU - Scheper,Thomas, AU - Meyer,Wolfgang, AU - Hadjigeorgiou,Georgios, AU - Bogdanos,Dimitrios P, AU - Sakkas,Lazaros I, Y1 - 2017/02/27/ PY - 2016/09/07/received PY - 2017/01/03/accepted PY - 2017/2/28/pubmed PY - 2017/12/22/medline PY - 2017/2/28/entrez SP - 31 EP - 34 JF - Clinical and experimental rheumatology JO - Clin Exp Rheumatol VL - 35 Suppl 106 IS - 4 N2 - OBJECTIVES: To study immunoreactivity against human cytomegalovirus (HCMV) in systemic sclerosis (SSc), since HCMV has been put forward as a candidate infectious cause. METHODS: Eighty four patients with SSc (67 females; median age 60 years, range 25-81), 30 patients with multiple sclerosis (MS) (23 females; median age 44, range 20-69 years) and 28 healthy controls (NCs), all pre-tested positive for IgG anti-HCMV antibodies, were studied. IgG anti-UL83 HCMV antibodies were tested by western immunoblotting and expressed in arbitrary units (AUs). Reactivity to UL83 HCMV was assessed in relation to clinical manifestations and SSc-related autoantibodies (autoAbs), tested by an IgG SSc autoantibody profile line immunoassay (Euroimmun) that detects autoAbs against Scl-70, CENPA, CENPB, RNA polymerase III subunit 11 (RP11), RP155, fibrillarin, NOR90, Th/To, PM-Scl100, PM-Scl75, Ku, PDGFR and Ro-52. RESULTS: Fifty patients (59.5%) were anti-UL83 clear positive (UL83+), including 21/40 (52.5%) lcSSc and 29/44 (65.6%) dcSSc, compared to 15/30 (50%) patients with MS (SSc vs MS, p=ns and 11/28 (39.29%) of NCs (SSc vs NC, p=ns MS vs NC, p=ns). Anti-UL83 antibody AU levels (mean±SD) were higher in SSc (64.3 ± 26) compared to MS (49.1±21.6, p=0.05) or NCs (40.4±13.7, p<0.001; MS vs NCs, p=ns) and were associated with pulmonary fibrosis. CONCLUSIONS: Immunoreactivity to UL83 HCMV is frequent and strong in patients with SSc, implying a possible pathogenic role for this disease. SN - 0392-856X UR - https://www.unboundmedicine.com/medline/citation/28240591/Increased_immunoreactivity_against_human_cytomegalovirus_UL83_in_systemic_sclerosis_ L2 - http://www.clinexprheumatol.org/pubmed/find-pii.asp?pii=28240591 DB - PRIME DP - Unbound Medicine ER -